33 results about "Hepatitis C virus RNA" patented technology

By administering a composition comprising pumpkin seed, safflower, plantain and honeysuckle, subjective symptoms (for example, general malaise and abdominal swelling) of a patient with chronic hepatitis C can be eliminated and, moreover, objective symptoms diagnosed by a medical doctor (for example, liver enlargement and palm erythema) can be relieved or eliminated. From 1 to 3 months after the administration of the composition, a significant decrease in hepatitis C virus RNA level is gradually observed. Therefore, the above composition is useful at least as a composition for treating chronic hepatitis C. In particular, it is advantageous in treating a chronic hepatitis C patient showing a high chronic hepatitis C virus RNA level.

The invention relates to a hepatitis C virus RNA extracting kit, belongs to the field of biomedical detection and relates to the nucleic acid isolation technology, particularly to the hepatitis C virus RNA extracting technology. By combining guanidine hydrochloride with a citric acid buffer system, the hepatitis C virus RNA extracting kit achieves the technical effects of effectively extracting hepatitis C virus RNA in samples in high security, high sensitivity and high stability.

The invention discloses an isothermal chain multiple displacement detection card of pathogen nucleic acid. The isothermal chain multiple displacement detection card of the pathogen nucleic acid utilizes the detection card which is prepared through a nucleic acid isothermal chain displacement method and a colloidal gold detection technology to carry out multiple detection on HBV-DNA, HCV-RNA, HIV-RNA, and TP-DNA. The isothermal chain multiple displacement detection card of the pathogen nucleic acid has the characteristics of simple and rapid operation, high sensitivity, and no need of professional equipment. The pathogen nucleic acid to be detected is not amplified in the detection process, so the detection card has the advantages of preventing amplified matter cross contamination in laboratories and preventing false positivity, can be widely used in high sensitivity pathogen nucleic acid detection in the fields of clinical detection, inspection and quarantine, infectious disease control, biological technology and the like, and has a wide application prospect.

The invention discloses a hepatitis C sequencing and typing kit which comprises: (1) primers of specific amplified hepatitis C virus RNA reverse transcription product c DNA and (2) hepatitis C virus specific sequencing primers, wherein the nucleotide sequences of the primers of specific amplified hepatitis C virus RNA reverse transcription product c DNA are shown as SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:4, the SEQ ID NO:1 and the SEQ ID NO:2 are a primer pair and the SEQ ID NO:3 and the SEQ ID NO:4 are another primer pair; and the nucleotide sequences of the hepatitis C virus specific sequencing primers are shown as SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:7; the SEQ ID NO:4 is marked with a biotin at a 5' end; and all the primers are all used in a detection. The invention also discloses a detection method of the hepatitis C sequencing and typing kit. The hepatitis C sequencing and typing kit can be used for sequencing and typing hepatitis C, thereby providing more comprehensive reference information for clinical diagnosis and treatment.

A method for detecting a mutation in an amino acid at position 93 of a hepatitis C virus NS5A protein, the method including:synthesizing cDNA using, as a template, hepatitis C virus RNA in a sample; andperforming a real-time PCR with a cycling probe method using, as a template, the cDNA;wherein a primer set used in the real-time PCR is a certain primer set; andwherein probes used in the real-time PCR include certain probes.

The invention provides a detecting method and an application of the extraneous activity of the RNA polymerase relied on by the hepatitis C virus RNA, which relates to an secure and practical establishing method for the detection of the activity extraneous detection of the RNA polymerase relied on by the hepatitis C virus RNA, and the application relates to the genetic engineering technology and the nanometer segregation enrichment and RNA related technology field. The invention expresses the soluble NS5B protein through the utilization of the genetic engineering technology, and prepares the nanometer magnetic particle. One end of a RNA template is fixed on the nanometer magnetic particle, and added in the 96 hole reaction plate micromesh, and added with NS5B protein to compose a RNA duplication system, and a duplicated RNA double chain on the nanometer magnetic particle is mixed with marked biological elements. After the RNA is duplicated, the nanometer magnetic particle is attached at the micromesh bottom through an external magnetic field magnet, after repeatedly cleaning and attaching, the nanometer magnetic particle is combined with the marked combining factor of the horse radish peroxidase, after attaching and cleaning, the substrate constant of the horse radish peroxidase is added to develop color. New NS5B protease activity inhibitor can be screened from a traditional Chinese storeroom and a compound storeroom by the established method.

The invention relates to compounds of the formula 1and to pharmaceutically acceptable salts, solvates, prodrugs and metabolites thereof, wherein W, Z, R1 and R2, are as defined herein. The invention also relates to methods of treating Hepatitis C virus in mammals by administering the compounds of formula 1, and to pharmaceutical compositions for treating such disorders, which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.

A gold nanoparticle-based colorimetric assay kit for hepatitis C virus RNA that detects unamplified HCV RNA in clinical specimens using unmodified AuNPs and oligotargeter polynucleotides that bind to HCV RNA. A method for detecting hepatitis C virus comprising contacting a sample suspected of containing hepatitis C virus with a polynucleotide that binds to hepatitis C virus RNA and with gold nanoparticles, detecting the aggregation of nanoparticles, and detecting hepatitis C virus in the sample when the nanoparticles aggregate (solution color becomes blue) in comparison with a control or a negative sample not containing the virus when nanoparticles do not aggregate (solution color remains red).

The invention discloses a truncated type hepatitis c virus HCV NS3 antigen which is a nonstructural protein amino acid sequence of the NS3 full-length gene encoded 1252th-1526aath segment in an HCV genome. The amino acid sequence is shown as SEQ ID NO.1, and a corresponding nucleotide sequence is shown as SEQ ID NO.2. A preparation method of HCV NS3 recombinant antigen protein comprises the steps that an optimized escherichia coli codon for expressing the truncated type hepatitis c virus HCV NS3 antigen are established, the nucleotide sequence of the codon is shown as SEQ ID NO.3, the gene segment of the codon undergoes double enzyme digestion and then is connected with an expression vector undergoing the enzyme digestion as well to obtain a recombinant expression plasmid, the antigen can perform expression by adopting a conventional method, and the antigen protein is obtained through purification. The antigen protein has high sensitivity and good specificity and is used for detecting an HCV antibody, and the coincidence rate of a detection result of a patient with positive hepatitis c virus RNA is as high as 97%. It is indicated that the antigen can be applied to polyclonal or monoclonal antibodies and preparation of hepatitis c virus detection kits and has good prospect of clinical application.

The present invention provides compounds of formula (4), and their pharmaceutically acceptable salts and solvates, which are useful as inhibitors of the Hepatitis C virus (HCV) polymerase enzyme and are also useful for the treatment of HCV infections in HCV-infected mammals. The present invention also provides pharmaceutical compositions comprising compounds of formula (4), their pharmaceutically acceptable salts and solvates. Furthermore, the present invention provides intermediate compounds and methods useful in the preparation of compounds of formula (4).

The invention discloses a fusion antigen of the first hypervariable region of hepatitis C virus. The amino acid sequence of the fusion antigen is shown in SEQ ID No.1. The invention also discloses the detection of the fusion antigen in the preparation of hepatitis C virus HVR1 antibody. application in the kit. It is verified by experiments that the cross-reactivity of the fusion antigen of the present invention is significantly improved compared with the single fragment HVR1 antigen, and the detection coincidence rate with hepatitis C virus RNA-positive patients is as high as 99%. Since HVR1 is the main neutralizing epitope in hepatitis C virus, through the application of the antigen of the present invention, for the detection of hepatitis C virus HVR1 antibody, the purpose of comprehensive detection of HCV infection can be realized, and it can be used for the transformation of HCV disease. Problems such as reconciliation prognosis and interferon curative effect prediction can be effectively solved, and have great clinical application prospects.